![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 19
2018
Peter, B.; Bibi, S.; Eisenwort, G.; Wingelhofer, B.; Berger, D.; Stefanzl, G.; Blatt, K.; Herrmann, H.; Hadzijusufovic, E.; Hoermann, G.; Hoffmann, T.; Schwaab, J.; Jawhar, M.; Willmann, M.; Sperr, W. R.; Zuber, J.; Sotlar, K.; Horny, H-P; Moriggl, R.; Reiter, A.; Arock, M. und Valent, P.
(2018):
Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells.
In: Leukemia, Bd. 32, Nr. 4: S. 1016-1022
Kaivers, J.; Lauseker, Michael; Hildebrandt, B.; Fenaux, P.; Pfeilstöcker, M.; Valent, P.; Platzbecker, U.; Latagliata, R.; Oliva, E. N.; Xicoy, B.; Götze, K.; Ganster, C.; Haase, D.; Bug, G.; Kündgen, A.; Gattermann, N.; Haas, R. und Germing, U.
(2018):
The IPSS-R has prognostic impact in untreated patients with MDS del(5q).
In: Leukemia Research, Bd. 72: S. 27-33
2017
Reiter, A.; Kluin-Nelemans, H. C.; George, T.; Akin, C.; DeAngelo, D. J.; Hermine, O.; Awan, F.; Hexner, E.; Mauro, M.; Schwaab, J.; Jawhar, M.; Sternberg, D.; Berkowitz, N.; Niolat, J.; Labed, A. Huntsman; Hartmann, K.; Horny, H.-P.; Valent, P. und Gotlib, J.
(2017):
Pooled Survival Analysis Of Midostaurin Clinical Study Data (D2201+A2213) In Patients With Advanced Systemic Mastocytosis Compared With Historical Controls.
In: Haematologica, Bd. 102: S. 321-322
Rabenhorst, A.; Sperr, W.; Elberink, J. Oude; Lange, M.; Gleixner, K.; Brazzelli, V.; Fontana, E.; Vos, B.; Gorska, A.; Reiter, A.; Schwaab, J.; Zanotti, R.; Bonadonna, P.; Triggiani, M.; Gotlib, J.; Doubek, M.; Jakob, T.; Kilbertus, A.; Sabato, V.; Zink, A.; Bretterklieber, A.; Jäkel, N.; Sotlar, K.; Horny, H.; Fortina, A. Belloni; Merante, S.; Niedoszytko, M.; Kluin-Nelemans, H.; Valent, P. und Hartmann, K.
(2017):
Age at disease onset has a major impact on clinical characteristics and course of mastocytosis.
In: Experimental Dermatology, Bd. 26, Nr. 3, E6-E6
Valent, P.; Sotlar, K.; Blatt, K.; Hartmann, K.; Reiter, A.; Sadovnik, I.; Sperr, W. R.; Bettelheim, P.; Akin, C.; Bauer, K.; George, T. I.; Hadzijusufovic, E.; Wolf, D.; Gotlib, J.; Mahon, F.-X.; Metcalfe, D. D.; Horny, H.-P. und Arock, M.
(2017):
Proposed diagnostic criteria and classification of basophilic leukemias and related disorders.
In: Leukemia, Bd. 31, Nr. 4: S. 788-797
Niedoszytko, M.; Gorska, A.; Nedoszytko, B.; Rabenhorst, A.; Sperr, W.; Elberink, Oude J.; Lange, M.; Gleixner, K.; Brazzelli, V; Fontana, E.; Vos, B.; Reiter, A.; Schwaab, J.; Zanotti, R.; Bonadonna, P.; Triggiani, M.; Gotlib, J.; Doubek, M.; Jakob, T.; Fuchs, D.; Sabato, V; Zink, A.; Bretterklieber, A.; Jäkel, N.; Sotlar, K.; Horny, H.; Fortina, Belloni A.; Merante, S.; Kluin-Nelemans, H.; Valent, P. und Hartmann, K.
(2017):
Impact of allergic disorders and anaphylaxis in mastocytosis: Preliminary data from a study of the European Competence Network on Mastocytosis (ECNM) registry.
In: Allergy, Bd. 72: S. 212-213
Gorska, A.; Gruchala-Niedoszytko, M.; Niedoszytko, M.; Rabenhorst, A.; Sperr, W.; Elberink, Oude J.; Lange, M.; Gleixner, K.; Brazzelli, V; Fontana, E.; Vos, B.; Reiter, A.; Schwaab, J.; Zanotti, R.; Bonadonna, P.; Triggiani, M.; Gotlib, J.; Doubek, M.; Jakob, T.; Fuchs, D.; Sabato, V; Zink, A.; Bretterklieber, A.; Jäkel, N.; Sotlar, K.; Horny, H.; Fortina, Belloni A.; Merante, S.; Kluin-Nelemans, H.; Valent, P. und Hartmann, K.
(2017):
The body mass index is an indicator of advanced systemic mastocytosis: preliminary results from a registry project of the European Competence Network on Mastocytosis (ECNM) registry.
In: Allergy, Bd. 72: S. 126-127
Valent, P.; Akin, C.; Hartmann, K.; George, T. I.; Sotlar, K.; Peter, B.; Gleixner, K. V.; Blatt, K.; Sperr, W. R.; Manley, P. W.; Hermine, O.; Kluin-Nelemans, H. C.; Arock, M.; Horny, H.-P.; Reiter, A. und Gotlib, J.
(2017):
Midostaurin: a magic bullet that blocks mast cell expansion and activation.
In: Annals of Oncology, Bd. 28, Nr. 10: S. 2367-2376
2016
Naumann, N.; Jawhar, M.; Schwaab, J.; Metzgeroth, G.; Khaled, N.; Horny, H.-P.; Sotlar, K.; Valent, P.; Haferlach, C.; Göhring, G.; Schlegelberger, B.; Meggendorfer, M.; Cross, N. C. P.; Hofmann, W. K.; Reiter, A. und Fabarius, A.
(2016):
Incidence and prognostic impact of cytogenetic aberrations in systemic mastocytosis.
In: Oncology Research and Treatment, Bd. 39: S. 25
Jawhar, M.; Schwaab, J.; Hausmann, D.; Clemens, J.; Naumann, N.; Henzler, T.; Horny, H.-P.; Sotlar, K.; Schoenberg, S. O.; Cross, N. C. P.; Fabarius, A.; Hofmann, W.-K.; Valent, P.; Metzgeroth, G. und Reiter, A.
(2016):
Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis.
In: Oncology Research and Treatment, Bd. 39: S. 232
Jawhar, M.; Schwaab, J.; Hausmann, D.; Clemens, J.; Naumann, N.; Henzler, T.; Horny, H. P.; Sotlar, K.; Schoenberg, S. O.; Cross, N. C.; Fabarius, A.; Hofmann, W. K.; Valent, P.; Metzgeroth, G. und Reiter, A.
(2016):
Splenomegaly and elevated alkaline phosphatase are strong and independent adverse prognostic markers in patients with systemic mastocytosis.
In: Haematologica, Bd. 101: S. 559
Jawhar, M.; Schwaab, J.; Hausmann, D.; Clemens, J.; Naumann, N.; Henzler, T.; Horny, H.-P.; Sotlar, K.; Schoenberg, S. O.; Cross, N. C. P.; Fabarius, A.; Hofmann, W.-K.; Valent, P.; Metzgeroth, G. und Reiter, A.
(2016):
Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis.
In: Leukemia, Bd. 30, Nr. 12: S. 2342-2350
Jawhar, M.; Schwaab, J.; Schnittger, S.; Meggendorfer, M.; Pfirrmann, Markus; Sotlar, K.; Horny, H. P.; Metzgeroth, G.; Kluger, S.; Naumann, N.; Haferlach, C.; Haferlach, T.; Valent, P.; Hofmann, W. K.; Fabarius, A.; Cross, N. C. und Reiter, A.
(2016):
Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis.
In: Leukemia, Bd. 30, Nr. 1: S. 136-143
2013
Schwaab, J.; Schnittger, S.; Sotlar, K.; Walz, C.; Fabarius, A.; Pfirrmann, Markus; Kohlmann, A.; Grossmann, V.; Meggendorfer, M.; Horny, H. P.; Valent, P.; Jawhar, M.; Teichmann, M.; Metzgeroth, G.; Erben, P.; Ernst, T.; Hochhaus, A.; Haferlach, T.; Hofmann, W. K.; Cross, N. C. und Reiter, A.
(2013):
Comprehensive mutational profiling in advanced systemic mastocytosis.
In: Blood, Bd. 122, Nr. 14: S. 2460-2466
2012
Germing, U.; Lauseker, Michael; Hildebrandt, B.; Symeonidis, A.; Cermak, J.; Fenaux, P.; Kelaidi, C.; Pfeilstöcker, M.; Nösslinger, T.; Sekeres, M.; Maciejewski, J.; Haase, D.; Schanz, J.; Seymour, J.; Kenealy, M.; Weide, R.; Lübbert, M.; Platzbecker, U.; Valent, P.; Götze, K.; Stauder, R.; Blum, S.; Kreuzer, K. A.; Schlenk, R.; Ganser, A.; Hofmann, W. K.; Aul, C.; Krieger, O.; Kundgen, A.; Haas, R.; Hasford, Joerg und Giagounidis, A.
(2012):
Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study.
In: Leukemia, Bd. 26, Nr. 6: S. 1286-1292
Horny, H. -P.; Sotlar, K. und Valent, P.
(2012):
Evaluation of Mast Cell Activation Syndromes: Impact of Pathology and Immunohistology.
In: International Archives of Allergy and Immunology, Nr. 1: S. 1-5
[PDF, 106kB]
2010
Horny, H. -P.; Sotlar, K. und Valent, P.
(2010):
Differential Diagnoses of Systemic Mastocytosis in Routinely Processed Bone Marrow Biopsy Specimens: A Review.
In: Pathobiology, Nr. 4: S. 169-180
[PDF, 1MB]
2007
Steidl, C.; Schanz, J.; Pfeilstöcker, M.; Nösslinger, T.; Hildebrandt, B.; Kuendgen, A.; Lübbert, M.; Giagounidis, A.; Aul, C.; Trümper, L.; Krieger, O.; Stauder, R.; Müller, Thomas H.; Wiamzal, F.; Valent, P.; Fonatsch, C.; Germing, U. und Hasse, D.
(2007):
Growing evidence for an underestimation of poor-risk cytogenetics in the international prognostic scoring system in myelodysplastic syndromes.
In: Clinical Leukemia, Bd. 1, Nr. 6: S. 353-356
2005
Germing, U.; Hildebrandt, B.; Pfeilstöcker, M.; Nösslinger, T.; Valent, P.; Fonatsch, C.; Lübbert, M.; Haase, D.; Steidl, C.; Krieger, O.; Stauder, R.; Giagounidis, A. A.; Strupp, C.; Kündgen, A.; Mueller, T.; Haas, R.; Gattermann, N. und Aul, C.
(2005):
Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS).
In: Leukemia, Bd. 19, Nr. 12: S. 2223-2231